Fenofibrate, a clinically approved peroxisome proliferator-activated receptor-alpha (PPARα) agonist used in the treatment of dyslipidemia,14 has demonstrated anti-inflammatory properties across multiple disease models.15,16 Previous work from our group showed that fenofibrate attenuates periodontal inflammation and bone loss in Pg-induced ligature models,17,18 yet the molecular mechanisms responsible for this protective effect remain unclear. This evidence concerns the gene PPARA and metabolic syndrome.